Clinical guideline
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
J Natl Compr Canc Netw · 2025
Studies and guidelines: Head and neck cancers
27 items with a structured summary · Head and neck cancers: the complete guide
Clinical guideline
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
ESMO Open · 2021
Other
DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers
Strahlenther Onkol · 2026
Clinical trial · Phase 3
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
Lancet · 2026
HR 0.76Disease-free survival
Other
Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689
J Clin Oncol · 2026
Review article
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer
Cancer Treatment Reviews · 2025
HR 0.73Event-free survival (EFS) in KEYNOTE-689
Clinical trial · Phase 3
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
N Engl J Med · 2025
59.8% vs 45.9%36-month event-free survival – CPS 10 or higher
Clinical trial · Phase 3
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
Eur J Cancer · 2025
HR 0.61 (CPS ≥20); 0.74 (CPS ≥1); 0.82 (total)Overall survival, pembrolizumab vs EXTREME
Clinical trial · Phase 3
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial
JCO · 2022
87.9% vs 78.8%5-year overall survival (induction chemotherapy vs concurrent chemoradiotherapy alone)
Review article
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management
Nat Rev Clin Oncol · 2022
Meta-analysis
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Radiother Oncol · 2021
HR 0.83Concurrent chemotherapy (main question)
Review article
Head and neck squamous cell carcinoma
Nat Rev Dis Primers · 2020
Review article
Nasopharyngeal carcinoma
The Lancet · 2019
Clinical trial · Phase 3
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
Lancet · 2019
77.9% vs 84.6%5-year overall survival
Clinical trial · Phase 3
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
The Lancet · 2019
4.8 (95% CI 4.2–5.4) with cisplatin vs 4.8 (4.2–5.4) with cetuximabOverall severe (grade 3 to 5) toxicity at 24 months (mean events per patient)
Clinical trial · Phase 3
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
N Engl J Med · 2016
7.5 vs 5.1 monthsMedian overall survival
Clinical trial
PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer
N Engl J Med · 2016
84.9% (95% CI: 80.7 to 89.1) in the surveillance group vs 81.5% (95% CI: 76.9 to 86.3) in the planned surgery group2-year overall survival
Clinical trial
Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
JCO · 2013
10.8 yearsMedian follow-up of surviving patients
Observational study
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
JCO · 2011
From 16.3% in 1984 to 1989 to 71.7% in 2000 to 2004HPV prevalence by Inno-LiPA
Observational study
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
N Engl J Med · 2010
70.3% vs 64.3%3-year overall survival: accelerated vs standard radiotherapy
Other
Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium
Cancer Epidemiology, Biomarkers & Prevention · 2009
2.15Multiplicative interaction of tobacco and alcohol (psi)
Clinical trial · Phase 3
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
N Engl J Med · 2008
10.1 months vs 7.4 months (cetuximab plus chemotherapy vs chemotherapy alone)Median overall survival
Clinical trial · Phase 3
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
N Engl J Med · 2006
24.4 months vs 14.9 months (cetuximab + radiotherapy vs radiotherapy alone)Median duration of locoregional control
Clinical trial · Phase 3
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
N Engl J Med · 2004
47% vs 36%5-year progression-free survival
Clinical trial · Phase 3
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial
JAMA · 2023
21.4 vs 8.2 monthsMedian progression-free survival (final PFS analysis)
Clinical trial · Phase 3
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
N Engl J Med · 2019
85.3% vs 76.5%3-year recurrence-free survival
Clinical trial · Phase 3
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Lancet · 2019
14.9 vs 10.7 monthsPembrolizumab monotherapy, overall survival (CPS ≥20)
Nothing found.